VPIM
NRSN icon

Vanguard Personalized Indexing Management’s NeuroSense Therapeutics NRSN Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,192
Closed -$16.7K – 1533
2023
Q2 		$16.7K Hold
11,192
– – ﹤0.01% 1456
2023
Q1 		$19.3K Hold
11,192
– – ﹤0.01% 1444
2022
Q4 		$13.7K Sell
11,192
-5,340
-32% -$8.49K ﹤0.01% 1262
2022
Q3 		$30K Sell
16,532
-23,102
-58% -$47.3K ﹤0.01% 1207
2022
Q2 		$134K Buy
+39,634
New +$75.1K 0.01% 1183

Other funds holding NRSN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Vanguard Personalized Indexing Management's NRSN Position: Q3 2023 in Review

Vanguard Personalized Indexing Management sold out of NeuroSense Therapeutics (NRSN) in Q3 2023, closing a stake of 11,192 shares — an estimated $16.7K sold.

Vanguard Personalized Indexing Management first reported a position in NRSN in Q2 2022 and held it in 5 quarters. The position peaked at $134K in Q2 2022. 5 funds tracked by Wall St. Rank hold NRSN as of Q3 2023.

  • Vanguard Personalized Indexing Management reported no remaining NeuroSense Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 11,192 NeuroSense Therapeutics shares in Q3 2023, an estimated $16.7K.
  • Vanguard Personalized Indexing Management first reported a position in NeuroSense Therapeutics in Q2 2022 and held it in 5 quarters.
  • Vanguard Personalized Indexing Management's NeuroSense Therapeutics position peaked at $134K in Q2 2022.
  • 5 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2023.

Based on Vanguard Personalized Indexing Management's 13F filing for Q3 2023, filed 8 Nov 2023.